美国医生与药师合作实践协议的模式与实施  

The mode and practice of physicians-pharmacists collaborative practice agreement in the United States

作　　者：董淑杰[1] 陆芸[2] 赵荣生[1] DONG Shu-jie;LU Yun;ZHAO Rong-sheng(Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China;College of Pharmacy,University of Minnesota,Minnesota Minneapolis 55415,USA)

机构地区：[1]北京大学第三医院药剂科,北京100191 [2]明尼苏达大学药学院,明尼苏达明尼阿波利斯55415

出　　处：《临床药物治疗杂志》2018年第12期57-60,共4页Clinical Medication Journal

摘　　要：药物治疗合作管理实质上是药师在合作实践协议框架的授权下,承担患者药物治疗管理的职责。在美国,医师或其医疗团队可在与药师签订的合作实践协议中将部分处方权授予药师,由药师在协议许可的范围内为特定患者开具处方,延续处方或更改处方以及根据用药监测需要开具相关检验指标,确保药物治疗的有效和安全。美国签署合作实践协议的医院数量比例正在逐步增长,这增加了药学服务的范围,促进了合作医疗的发展。美国的医生与药师合作实践协议的模式与实施已经获得了成功,值得我国的医院和药师借鉴。Pharmacists take responsibility for collaborative drug therapy management under the authorization of collaborative practice agreement.In the United States,pharmacists are able to get limited prescription rights by signing collaborative practice agreements with physicians or medical teams,and then pharmacists can prescribe,refill or change the medications,In addition,relevant examination should be prescribed according to the need of drug use monitoring to ensure the drug treatment to be effective and safe.The proportion of hospitals in the United States that permit collaborative practice agreements is gradually increasing,which effectively broaden the scope of pharmacy service and promote the development of cooperative medical care.The practice of collaborative practice agreement model in the United States has been successful and set an example for hospitals and pharmacists in China.

关 键 词：药物治疗合作管理 合作实践协议 处方权 

分 类 号：R95[医药卫生—药学]